Overview

Use of Clarithromycin in Mustard-Induced Bronchiolitis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
Male
Summary
We looked for the effectiveness of low-dose long-term prescription of clarithromycin in mustard-induced chronic pulmonary lesions, especially bronchiolitis obliterans
Phase:
Phase 3
Details
Lead Sponsor:
Baqiyatallah Medical Sciences University
Treatments:
Clarithromycin
Criteria
Inclusion Criteria:

- His/her own will to participate

- Documented chemical exposure

- Clinical, spirometric and radiological findings were compatible with BO on High
Resolution Computed Tomography (HRCT)

Exclusion Criteria:

- any drug reactions during the trial

- history of sensitivity to macrolides

- diarrhea, gray stool, jaundice, eosinophilia, acute cholestatic hepatitis, pruritis,
dark urine, abdominal pain, osteomatosis, depression, taste change, behavioural
changes, early fatigue, odynophagia, glossitis , dizziness

- co-adminstration of: terfenadine, theophylline, carbamazepine, ergotamine,
dihydroergotamine, warfarin, cisapride, digoxin, triazolam, phenytoin, steroids, any
immunosuppressive, any systemic antibiotics

- using drugs that he/she cannot discontinue

- using drugs with potential interaction

- subject will to exit from the trial

- history of lobe resection of lung

- history of exacerbation in the last month prior to the beginning of trial

- continuous need to oxygen

- use of corticosteroids in last week prior to the trial beginning

- Radiographic evidence of pneumonia, active tuberculosis, lung carcinoma, or an
infection that necessitated the use of an antibiotic

- exacerbating of subjects

- creatinine srum level more than normal

- increasing ALT, AST levels

- total bilirubin more twice than normal

- subjects who did not use their drugs properly